TRIAXIS

This brand name is authorized in Austria, Spain, Finland, Ireland

Active ingredients

The drug TRIAXIS contains a combination of these active pharmaceutical ingredients (APIs):

1 Pertussis acellular (pertussis toxin (FHA) 69 KDA outer membrane protein)

Read about Pertussis toxoid

2 Filamentous hæmagglutinin (FHA) UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

3 Adsorbed purified pertactin (PRN) UNII 2QNL82089R - BORDETELLA PERTUSSIS

Read about Pertactin

4 Diphtheria toxoids adsorbed UNII 3U7E3O07S8 - CORYNEBACTERIUM DIPHTHERIAE

Read about Diphtheria toxoid

5 Tetanus toxoid adsorbed UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07AJ52	Pertussis, purified antigen, combinations with toxoids	J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AJ Pertussis vaccines
Discover more medicines within J07AJ52

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 81067
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 053401